Biopharmaceutical initial public offerings (IPOs) saw an upturn in 2024, with 50 completed IPOs raising a total of $8.52 ...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...

Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...

Minister of Further and Higher Education, Research, Innovation and Science, James Lawless, TD, has announced €1m funding to ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities analyst Tim Anderson sees promise for a handful of large-cap competitors.

China has achieved remarkable strides in biopharmaceutical innovation in recent years to better safeguard the health of its people, a member of the country's top political advisory body said on ...

Privo Technologies, a phase 3 clinical-stage biopharmaceutical company specializing in drug delivery and cancer treatment in ...

SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.